Browsing by Subject
Ara mostrant els elements 1-20 d 31
-
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer
(Future Medicine, 2023-08) -
A pragmatic guide for management of adverse events associated with lorlatinib
(Elsevier, 2024-03-14) -
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
(Wolters Kluwer Health, 2021-08) -
Confounding factors in the assessment of oral mucositis in head and neck cancer
(Springer, 2022-10) -
Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
(Frontiers Media, 2023-01-05) -
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
(American Association for Cancer Research, 2021-12) -
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
(Future Medicine, 2022-09) -
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
(American Society of Hematology, 2022-09-13)